Young Chan Kim

Lecturer in Medicine (Somerville); Sir Henry Wellcome Fellow; Junior Research Fellow (Wolfson); Senior Postdoctoral Fellow; NHS Doctor

I am a Sir Henry Wellcome Fellow, a Junior Research Fellow (JRF) at Wolfson College, a Senior Postdoctoral Fellow, and an NHS doctor.

I completed a BSc degree in Biochemistry from Imperial College London and my medical degrees (BMBS, BMedSci and MRes) from the University of Nottingham. I then spent few years working in junior doctor posts before coming to Oxford to start a DPhil in Clinical Medicine (Somerville College). I have always been very keen on combining clinical medicine with a career in research. My DPhil studies focused on vaccine development against arthropod-borne viruses supported by Innovate UK funding. I was awarded highly prestigious NDM Graduate Student Prize 2020 (Overall Prize Winner) for my overall performance during my DPhil degree at the Nuffield Department of Medicine (NDM) and a NIHR Oxford BRC Grant to support my research as a Postdoctoral Fellow. In 2022, I was awarded the Sir Henry Wellcome Fellowship to start my independent research on vaccine development against emerging arboviruses at the NDM. I am now a Sir Henry Wellcome Fellow, a Junior Research Fellow (JRF) at the Wolfson College, a Senior Postdoctoral Researcher, and a doctor in Internal Medicine at the Oxford University Hospitals NHS Foundation Trust.


Publications

  • López-Camacho C & Kim YC, et al.(2019). Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus. Viruses, 11 (4). Kim YC, et al A.(2020).
  • COVID-19 Vaccines: Breaking Record Times to First-in-Human Trials. NPJ Vaccines, 5, 34. Kim YC, et al (2020).
  • Evaluation of Chimpanzee Adenovirus and MVA Expressing TRAP and CSP from Plasmodium Cynomolgi to Prevent Malaria Relapse in Nonhuman Primates. Vaccines (Basel), 8 (3). Folegatti P, et al.(2021).
  • A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. Nat Commun. 12, 4636 2021. Kim YC, et al (2022).
  • Development of novel viral vectored vaccines and virus replicon particle-based neutralization assay against Mayaro virus. Int. J. Mol. Sci. 2022, 23, 4105.


Where Next?